Medical Xpress

FEBRUARY 28, 2025

Dana-Farber investigators found that normally defunct viral genes that lie dormant in the human genome can be activated in the most common form of kidney cancer (clear cell renal cell carcinoma) and can end up triggering an immune response against the cancer.

Genome 89

Genome Genomics Immune Response DNA 89

Pharmaceutical Technology

APRIL 11, 2023

In August 2021, Zydus secured emergency use authorisation (EUA) from the Drugs Controller General of India for its Covid-19 deoxyribonucleic acid (DNA) plasmid vaccine, ZyCoV-D. The vaccine, which generates the SARS-CoV-2 viral spike protein on administration, induces the immune system’s cellular and humoral arm-mediated immune response.

FDA Approval 130

FDA Approval Drugs Immune Response Manufacturing 130

pharmaphorum

SEPTEMBER 14, 2021

Startup Rome Therapeutics has raised $77 million in second-round financing to help mine sequences of DNA – which were dismissed for years as ‘junk’ – for hidden treasure. Much of this repeatome is thought to derive from viruses that embedded in our DNA millions of years ago.

DNA 52

DNA Immune Response Genome Genomics 52

Pharmaceutical Technology

MAY 10, 2023

Gilead Sciences research executive vice-president Flavius Martin stated: “The team at XinThera has developed research assets with the potential to target the DNA damage repair pathway in treating cancer and direct the body’s immune response in inflammatory diseases, both of which may improve outcomes for people living with these diseases.

Immune Response 130

Immune Response DNA Clinical Trials Clinical Trials 130

XTalks

NOVEMBER 6, 2020

The Burnaby, BC-based company developed the oral DNA-based vaccine using its proprietary bacTRL Gene Therapy Platform, which uses genetically modified bifidobacteria as carriers of genetic vaccine elements on a DNA plasmid. Related: Red Meat Allergy Test Gets FDA Clearance. “We

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

Pharmaceutical Technology

FEBRUARY 3, 2023

Since HIV integrates with the DNA, eliminating the virus from the body is very difficult, explains David Montefiori, PhD, director of the Laboratory for AIDS Vaccine Research and Development at Duke University in Durham, North Carolina. The failure of several late-stage trials highlights the challenging nature of HIV vaccine development.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

pharmaphorum

FEBRUARY 22, 2021

In December interim phase 1/2 trial results showed the vaccine produced a lower immune response in older adults. At the time analysts said that this was likely due to an insufficient concentration of the antigen and the companies have refined their antigen formulation hoping for a better immune response including in older adults.

Vaccination 89

Vaccination Vaccine Recombinant DNA Technology Trials 89

Worldwide Clinical Trials

JUNE 21, 2024

Although there are a range of efficacies across different tumor types that require a greater understanding, the use of circulating tumor DNA profiles holds promise for personalized treatment strategies that better target the drug for the patient, potentially revolutionizing how ADCs are deployed in clinical practice.

Antibody 162

Antibody Clinical Trials Clinical Trials In-Vitro 162

pharmaphorum

FEBRUARY 23, 2022

Code Bio’s 3DNA vectors are based on pieces of synthetic DNA linked together to form a scaffold that can carry a larger gene sequence than viral vectors, and according to the biotech don’t trigger an immune response which might cause side effects or limit the potential for re-dosing.

Gene Therapy 105

Gene Therapy Gene Gene Sequencing Immune Response 105

The Pharma Data

DECEMBER 23, 2020

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” About INOVIO’s DNA Medicines Platform. mg and 2.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. The structural proteins include the capsid, pre-membrane/membrane proteins and envelope (E) proteins.

Vaccination 130

Vaccination Vaccine Protein Immune Response 130

pharmaphorum

OCTOBER 2, 2020

Vaccibody, which is also entitled to tiered royalties on sales of any marketed products, will develop the DNA-based individualised neoantigen vaccines until the end of phase 1b. Vaccibody has been working on a targeted DNA-based vaccine platform, in a bid to find a potential new treatment paradigm for individualised cancer vaccines.

Vaccination 59

Vaccination Vaccine Immune Response Drugs 59

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. The vaccine also contains other inactive ingredients such as cholesterol.

Vaccination 130

Vaccination Vaccine Containment Immune Response 130

Pharmaceutical Technology

NOVEMBER 22, 2022

When an mRNA vaccine is administered, a patient’s body produces that protein to prompt a desired immune response. There is also a potential for an unwanted immune response and allergic reaction following patient administration.

Manufacturing 130

Manufacturing Vaccine Vaccination RNA 130

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility.

Vaccination 116

Vaccination Vaccine Clinical Trials Clinical Trials 116

pharmaphorum

MAY 11, 2021

Laronde thinks that its new class of RNA – a transcript of DNA that can be read by the body and turned into proteins – will cut the number of injections required as the body will actively make the disease-fighting protein instead of passively requiring top-ups.

RNA 98

RNA Drugs Protein Immune Response 98

The Pharma Data

DECEMBER 20, 2020

SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology. UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . Source link.

Clinical Trials 52

Clinical Trials Clinical Trials Pharma Companies Vaccination 52

pharmaphorum

SEPTEMBER 29, 2020

The US drugs regulator has placed the phase 2/3 trial of INO-4800 on partial clinical hold while it seeks answers from the company about the DNA-based vaccine as well as the device used to deliver the shot to patients in the study. An expanded phase 1 trial of the shot is still ongoing and unaffected by the partial hold.

Vaccination 52

Vaccination Vaccine Trials DNA 52

XTalks

NOVEMBER 30, 2023

The noteworthy candidate, EBT-101, is designed to eliminate HIV proviral DNA using CRISPR-Cas9 along with two guide RNAs (gRNAs). These dual gRNAs target three specific sites within the HIV genome, facilitating the removal of substantial portions of the viral DNA and minimizing the potential for viral escape.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Pharmaceutical Technology

APRIL 18, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. These can serve as an important component of a vaccine.

Protein 147

Protein Vaccine Vaccination Production 147

Worldwide Clinical Trials

JUNE 15, 2022

Further, some patients are still hesitant to go into the clinic, and the prevalence of misinformation from the pandemic has led to greater concerns about therapies like gene therapies and the impact they fear it will have on their RNA/DNA.

Gene Therapy 130

Gene Therapy Gene Clinical Trials Clinical Trials 130

The Pharma Data

APRIL 8, 2021

Leadership in DNA damage response demonstrated in multiple presentations for AZD5305, a next-generation PARP1 selective inhibitor. Data for AZD5305 will demonstrate how the next wave of DNA damage response medicines can build on the success of PARP inhibitors, potentially allowing patients to stay on treatment longer.

DNA 52

DNA Medicine Genome Genomics 52

pharmaphorum

OCTOBER 12, 2022

The payload, Del Bourgo tell us, is the therapeutic DNA or RNA sequence that will cure or fix damaged cells. Similar to how we injected mRNA into people to trigger an immune response and train their immune system against COVID-19, genomic medicine repairs cellular or molecular mechanisms that are dysfunctional and cause disease.”.

Genome 105

Genome Genomics Medicine Development 105

pharmaphorum

AUGUST 27, 2020

Conventional vaccines introduce an inactivated sample of a disease to patients with the aim of stimulating an immune response. Today researchers are attaching only a portion of the DNA or mRNA of the virus to a harmless molecule. The first is that the development of vaccines is utilising cutting edge technologies.

Vaccination 122

Vaccination Vaccine Life Science Clinical Trials 122

Cloudbyz

MARCH 6, 2024

Unlike traditional small molecule drugs, which are chemically synthesized, biologics are produced through complex biotechnological processes, often involving recombinant DNA technology. Understanding Biologics: Biologics are a class of therapeutic agents derived from living organisms, such as cells, tissues, or proteins.

Gene 99

Gene Immune Response Manufacturing Gene Therapy 99

Find Me Cure

OCTOBER 13, 2019

An enzyme involved in DNA repair can be the key to making chemotherapy more effective. PARP inhibitors work by blocking the function of the PARP enzyme, thus preventing the repair of the tumour DNA. This way a chemotherapy drug that damages the DNA of the cancer cells has a higher chance of succeeding at killing the cells.

Development 52

Development DNA Clinical Trials Clinical Trials 52

Delveinsight

AUGUST 6, 2020

The Indian company informed that the DNA vaccine was well tolerated in the first stage of the adaptive phase 1/2 trial. ZyCoV-D is designed to introduce DNA that encodes for a viral protein into human cells. By ordering human cells to make the protein, ZyCoV-D could cause an immune response against the coronavirus.

Allergies 53

Allergies Vaccination Vaccine Gene Therapy 53

pharmaphorum

FEBRUARY 22, 2021

Lentiviral vectors have become a popular alternative for some therapies because they can deliver larger gene sequences into target cells and are less likely to stimulate an immune response in the patient that could affect their safety and efficacy. million in Europe.

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Expression 52

The Pharma Data

JANUARY 18, 2021

Next Generation AAVs enhance gene therapies by increasing transduction efficiency and specificity while reducing immune responses and cost. Use of AAVnerGene capsid library provided to Neurophth for ophthalmic gene therapy. WUHAN, China and NEWARK, DE. , a subsidiary of Wuhan Neurophth Biotechnology Ltd.

Gene Therapy 52

Gene Therapy Gene Immune Response Manufacturing 52

The Pharma Data

MAY 15, 2023

The team at XinThera has developed research assets with the potential to target the DNA damage repair pathway in treating cancer and direct the body’s immune response in inflammatory diseases, both of which may improve outcomes for people living with these diseases,” said Flavius Martin, M.D.,

DNA 40

DNA Immune Response Medicine Development 40

The Pharma Data

NOVEMBER 18, 2020

.” Ming-Tain Lai, PhD, Chief Scientific Officer at OBI Pharma stated, “In the trial, OBI-833 demonstrated a favorable safety profile and generated detectable anti-Globo H IgM/IgG responses. ” Presentation number: 397P / Poster: ID 680. Additional information can be found at www.obipharma.com. Forward-Looking Statements.

Vaccination 52

Vaccination Vaccine Immune Response Trials 52

The Pharma Data

JANUARY 13, 2021

The vaccine produced an immune response of all 805 clinical trial participants within two months of inoculation, according to results published Jan. More than 90% of participants mounted an immune response within a month, and all had levels of neutralizing antibodies by day 57. WEDNESDAY, Jan. vaccination efforts.

Vaccination 40

Vaccination Vaccine Trials Immune Response 40

XTalks

MARCH 10, 2021

Adaptive Biotechnologies’ T-Detect COVID Test is a next-generation sequencing (NGS) test that can indicate recent or prior infection with SARS-CoV-2 through detection of a T cell immune response to the virus. This is the first T cell test of its kind for the detection of COVID-19 infection.

Protein 98

Protein RNA Antibody Production 98

The Pharma Data

JANUARY 20, 2021

Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced the pricing of an underwritten public offering of 17,700,000 shares of its common stock at a public offering price of $8.50

DNA 40

DNA Containment Immune Response Sales 40

Roots Analysis

AUGUST 23, 2024

Unveiling The Potential of mRNA Technology mRNA is a single-stranded molecule that relays the genetic instructions needed to make proteins from DNA in the cell nucleus to ribosomes. In theory we could do this for any infectious disease where we know enough about what molecules provoke an effective immune response.

Protein 40

Protein Vaccination Vaccine Immune Response 40

Delveinsight

DECEMBER 3, 2020

AMD Patients often have low levels of CD59, which is a protein that protects the retina from damage caused by a vital part of the body’s natural immune response called complement. An overactivity of complement damages cells in the macula in geographic atrophy. Merck chooses TriNKET cancer immunotherapy program.

Gene Therapy 52

Gene Therapy Gene Antibody Research 52

Delveinsight

DECEMBER 13, 2020

Unlike a typical virus, hepatitis B’s cccDNA permanently integrates itself into a healthy cell’s DNA. HBV DNA can be integrated into the host genome. The complex nature and integration process of cccDNA contributes to the difficulties of finding a cure for hepatitis B. There are additional barriers to eliminating HBV.

Genotype 52

Genotype FDA Approval DNA Drugs 52